Lilly to divest baqsimi to amphastar

Lilly focused on delivering the company's unprecedented pipeline of next-generation medicines to help patients amphastar is the ideal company to continue lilly's mission to help more people benefit from baqsimi indianapolis and rancho cucamonga, calif. , april 24, 2023 /prnewswire/ -- in an effort to continue expanding the availability of baqsimi® to patients, eli lilly and company (nyse: lly) and amphastar pharmaceuticals, inc. (nasdaq: amph) have entered into a definitive agreement for lilly to divest baqsimi worldwide to amphastar, a global pharmaceutical company focused on developing, manufacturing, and marketing injectable, intranasal, and inhalation products including experience with a glucagon product.
AMPH Ratings Summary
AMPH Quant Ranking